US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,829.73

-1.9733-0.11%

Number of Gainers:8

Number of Losers:10

Number of Flat:1

PE:- -

High:1,847.82

Open:1,834.63

Low:1,827.63

Close:1,831.70

Volume:81.68M

Turnover:6.29B

Market Cap:1.49T

Float Cap:1.45T

Loading ...

Ocugen Doses First Patient in Trial of Potential Eye Disease Drug

MT Newswires Live

AstraZeneca completes global license agreement for Zegfrovy in lung cancer

Ocugen - Bla Filing for Ocu410 Anticipated in 2028

THOMSON REUTERS

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of Ocu410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

THOMSON REUTERS

Aethlon Medical Announces Annual Shareholder Meeting

AstraZeneca Reports 'Meaningful Improvement' in Phase 3 Study of Lung Cancer Patients

MT Newswires Live

AstraZeneca Says Breast Cancer Combo Approved in EU; Completes Acquisition of License for Lung Cancer Treatment

MT Newswires Live

Top 10 Best-Performing US Stocks in August: Moderna Surges 156%, Palantir Leads AI Software Stocks

American Tungsten & Antimony Taps Finland Firm for Scoping Study; Shares Up 4%

MT Newswires Live

Did Targeted XFG COVID Shots Just Recenter Pfizer's (PFE) Post‑Pandemic Investment Narrative?

Simply Wall St.

Novavax Inc. Stock Outperforms Competitors on Strong Trading Day

Inovio Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors

Pfizer Inc. Stock Outperforms Competitors on Strong Trading Day

Abbott Laboratories Stock Underperforms Monday When Compared to Competitors

Cboe data suggests bullish flow in Moderna with shares up 0.71%

Moderna Stock (MRNA) Was the Best Performer in August

AstraZeneca PLC Stock Rises Monday, Outperforms Market

Aethlon Medical Completes Warrant Exercises, Clarifying Capitalization

China's Ascletis Pharma H1 Net Loss Widens on Higher R&D Costs

Aethlon Medical Says All Pre-Funded Warrants are Exercised

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/BK4568/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1829.725,"timestamp":1789156799999,"preClose":1831.6982,"halted":0,"volume":81680616,"delay":0,"changeRate":-0.001077,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-1.973267,"latestTime":"09-11 16:00:00 EDT","open":1834.6257,"high":1847.822,"low":1827.6261,"amount":6287215226.103668,"amplitude":0.011026,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.765405,"peRate":46.412835,"turnoverRate":0.005888,"increases":8,"decrements":10,"flats":1,"marketCap":1488552354289,"floatMarketCap":1454499170180},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1847.822,"amplitude":0.011026,"preClose":1831.6982,"low":1827.6261,"pbRate":"4.765405","latestPrice":1829.725,"volume":81680616,"delay":0,"open":1834.6257,"prevYearClose":1637.1339,"prevWeekClose":1896.2245,"prevMonthClose":1860.7577,"prevQuarterClose":1731.2963,"fiveDayClose":1915.5433,"twentyDayClose":1778.1694,"sixtyDayClose":1663.0237,"secType":"PLATE","market":"US","turnoverRate":0.005888,"peRate":46.412835,"marketCap":1488552354289,"floatMarketCap":1454499170180,"timestamp":1789156799999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":8,"down":10,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664408855","title":"Ocugen Doses First Patient in Trial of Potential Eye Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2664408855","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664408855?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:35","pubTimestamp":1788262505,"startTime":"0","endTime":"0","summary":"Ocugen Inc  has dosed its first patient in a phase 3 trial of its OCU410 modifier gene therapy as a potential treatment for geographic atrophy secondary to dry age-related macular degeneration, the company said Tuesday.The drug is designed as a one-time subretinal gene therapy, the company said.The placebo-controlled study has enrolled 237 patients, the company said.The company plans to file a biologics license application for the therapy in 2028, it said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","OCGN","BK4563","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664555058","title":"AstraZeneca completes global license agreement for Zegfrovy in lung cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664555058","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664555058?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:10","pubTimestamp":1788261040,"startTime":"0","endTime":"0","summary":"AstraZeneca (AZN) announced the completion of the exclusive license agreement with Dizal Pharmaceutical for Zegfrovy – sunvozertinib -, an oral irr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-completes-global-license-agreement-for-zegfrovy-in-lung-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-completes-global-license-agreement-for-zegfrovy-in-lung-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443549.SGD","LU0128525929.USD","LU2417539215.USD","LU0058720904.USD","LU2237443895.HKD","LU2456880835.USD","BK4007","LU2237443465.HKD","AZNH","LU0310800379.SGD","LU0320765992.SGD","LU0289739699.SGD","LU0109394709.USD","LU0889565916.HKD","LU0029864427.USD","BK4585","AZN","LU2237443622.USD","LU0708994859.HKD","LU2468319806.SGD","LU1267930573.SGD","IE00B3T34201.USD","LU2236285917.USD","LU2089984988.USD","LU2237443382.USD","LU2462157665.USD","LU1829250122.USD","LU2237443978.SGD","BK4568","LU0432979614.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664853292","title":"Ocugen - Bla Filing for Ocu410 Anticipated in 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2664853292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664853292?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:02","pubTimestamp":1788260520,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nTUA1R23YC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","OCGN","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664185321","title":"Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of Ocu410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2664185321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664185321?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:02","pubTimestamp":1788260520,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nTUA1R23YC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCGN","BK4568","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664830033","title":"Aethlon Medical Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2664830033","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664830033?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:06","pubTimestamp":1788257173,"startTime":"0","endTime":"0","summary":"Aethlon Medical announces annual shareholder meetingAethlon Medical will hold its annual shareholder meeting virtually on Oct. 1, 2026.Shareholders will vote on electing five directors, ratifying audi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL4Y3hLN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4568","AEMD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664322228","title":"AstraZeneca Reports 'Meaningful Improvement' in Phase 3 Study of Lung Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2664322228","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664322228?lang=en_us&edition=fundamental","pubTime":"2026-09-01 17:01","pubTimestamp":1788253304,"startTime":"0","endTime":"0","summary":"AstraZeneca  said early Tuesday that Tagrisso plus Orpathys in a phase 3 trial showed a \"statistically significant and highly clinically meaningful improvement\" in progression-free survival versus tagrisso alone in a trial of newly diagnosed lung cancer patients.The SANOVO Phase 3 trial included 326 patients in China who had not previously been treated for advanced lung cancer with specific genetic changes, according to AstraZeneca.The benefit was seen in both the high MET and intention-to-treat trial populations, the company said. The combination also showed what the company described as very encouraging clinical benefit in overall survival, which is a secondary endpoint, although the trial will continue to follow patients.The safety profile for Tagrisso plus Orpathys was consistent with the known profiles of each medicine, and no new safety findings emerged.The results from the trial reinforce tagrisso as the backbone therapy across epidermal growth factor receptor-mutated lung cance","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0310800379.SGD","LU0889565916.HKD","LU0109394709.USD","AZNH","IE00B3T34201.USD","LU2417539215.USD","BK4007","LU1267930573.SGD","LU0058720904.USD","LU2468319806.SGD","LU2089984988.USD","BK4588","LU0320765992.SGD","LU0029864427.USD","LU2462157665.USD","LU0289739699.SGD","LU1829250122.USD","LU2236285917.USD","LU0432979614.USD","LU0708994859.HKD","LU2237443622.USD","LU2237443978.SGD","BK4568","LU2237443465.HKD","LU2237443895.HKD","LU0128525929.USD","LU2237443382.USD","AZN","LU2456880835.USD","LU2237443549.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664739831","title":"AstraZeneca Says Breast Cancer Combo Approved in EU; Completes Acquisition of License for Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2664739831","media":"MT Newswires Live","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664739831?lang=en_us&edition=fundamental","pubTime":"2026-09-01 15:58","pubTimestamp":1788249536,"startTime":"0","endTime":"0","summary":"AstraZeneca  and Daiichi Sankyo's combination of Enhertu plus pertuzumab has been approved in the European Union as a first-line treatment of patients with HER2-positive metastatic breast cancer, the companies said Tuesday.The approval triggers a $100 million milestone payment by AstraZeneca to Daiichi Sankyo. It was based on a phase 3 study that showed the drug combination reduced the risk of disease progression or death by 44% compared with the standard of care.Astrazeneca also said it has completed its previously announced worldwide exclusive license agreement with Dizal Pharamceutical for Zegfrovy, a treatment for patients with lung cancer.The company will make an upfront payment of $600 million to Dizal, along with additional payments of up to $900 million on achievement of specific development.Under the deal, Dizal will also receive royalties on sales of Zegfrovy, the company said.The payout does not impact AstraZeneca's 2026 financial guidance, it added.AstraZeneca shares were d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LU2456880835.USD","LU2237443465.HKD","LU2237443549.SGD","LU2462157665.USD","LU0708994859.HKD","LU0320765992.SGD","LU0432979614.USD","BK4588","BK4585","LU2236285917.USD","LU2089984988.USD","LU0029864427.USD","LU0289739699.SGD","LU1829250122.USD","LU0109394709.USD","BK4568","LU0310800379.SGD","LU0889565916.HKD","LU2237443382.USD","AZNH","LU1267930573.SGD","LU2237443895.HKD","AZN","LU0058720904.USD","LU0128525929.USD","IE00B3T34201.USD","LU2237443622.USD","LU2468319806.SGD","LU2237443978.SGD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664836115","title":"Top 10 Best-Performing US Stocks in August: Moderna Surges 156%, Palantir Leads AI Software Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2664836115","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664836115?lang=en_us&edition=fundamental","pubTime":"2026-09-01 14:51","pubTimestamp":1788245470,"startTime":"0","endTime":"0","summary":"TradingKey - In August 2026, the upward momentum in US stocks broadened significantly. Moderna (MRNA) topped the S&P 500 constituents with a 156% gain, surging 375.9% year-to-date. Palantir (PLTR) followed closely behind, rising 51.5% in August, while enterprise software stocks as a whole extended their previous recovery.","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230915/5159981a89101d628f3e4c33ac20272e.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230915/5159981a89101d628f3e4c33ac20272e.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/analysis/stocks/us-stocks/262143172-top-10-best-performing-us-stocks-august-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130103400.USD","FMTL","OPTZ","CRMG","LU2023251221.USD","LU0211327993.USD","LU1989772923.USD","BK4585","LU0724618789.USD","LU0742534661.SGD","LU1046421795.USD","LU1791710400.SGD","SNDQ","BK4503","LU1923622614.USD","IE00B19Z3B42.SGD","FSMD","LU1814569148.SGD","LU0642271901.SGD","LU1223082196.USD","LU1267930490.SGD","LU2362541513.USD","LU0154245756.USD","LU0266512473.USD","LU1720051017.SGD","LU2286300806.USD","LU0310799852.SGD","LU2361045086.USD","AGMI","BK4579","PLTW","IT","LU2023250504.SGD","WDNA","BK4550","LU2265009873.SGD","LU0124676726.USD","LU1496350502.SGD","LU1803068979.SGD","VEEV","LU1201861249.SGD","LU0300736062.USD","LU0265550359.USD","LU0348723411.USD","LU0672654240.SGD","BK4532","LU0266512127.USD","SG9999001143.SGD","LU1951198990.SGD","LU0719512351.SGD","LU0157215616.USD","IE00BZ9MQY76.HKD","LU2458330243.SGD","BK4533","LU1023059493.AUD","LU0330918003.SGD","LU0055631609.USD","BK4170","IE00BMPRXN33.USD","IE00BJTD4N35.SGD","PSKY","LU0472753341.HKD","LU2461242641.AUD","LU0109392836.USD","LU1883866441.USD","BK4167","PLT","BK4598","PLTZ","LU2264538146.SGD","LU2498475776.HKD","LU0127658192.USD","LU0980610538.SGD","LU2244417387.USD","BK4581","LU1861559042.SGD","LU2360107168.USD","TMSL","LU0345780950.USD","LU0107464264.USD","LU0477156953.USD","LU1917777945.USD","BK4504","LU0792757196.USD","LU1235294995.USD","LU0187121727.USD","LU0278409577.USD","LU1951200564.SGD","LU2247934214.USD","SLVP","LU0496367417.USD","EKG","BK4097","LU1116320901.HKD","LU2361044865.SGD","LU1548497426.USD","BK4534","LU0170899867.USD","AIPI","BK4566","LU0477156797.USD","LGHT","LU0238689110.USD","LU0128525689.USD","LU2063271972.USD","LU0289961442.SGD","LU2089283258.USD","GDX","NWMX","LU2361044949.HKD","LU2125909247.SGD","LU0612318385.USD","LU0320765059.SGD","LU2362541273.HKD","LU0266013472.USD","LU2433249047.HKD","LU1989764748.USD","NEMG","LU0788108826.HKD","LU2756315318.SGD","LU2517655028.SGD","LU1720051108.HKD","LU2125909916.SGD","SNDG","LU1201861165.SGD","DISK","LU0316494557.USD","LU1366333091.USD","BK4528","LU0265550946.USD","GNOM","SMCC","BK4505","IGV","PLTR","LU0081259029.USD","LU2028103732.USD","COWG","LU0130518102.USD","LU2125909593.SGD","LU0106261372.USD","LU0820561818.USD","LU0820561909.HKD","LU0456854461.SGD","BK4570","LU0557290698.USD","BK4568","BK4501","SNDC","EYES","LU0251131958.USD","LU1323610961.USD","LU1974910355.USD","LU0069063385.USD","BK4543","LU1791710582.SGD","IE00BQXX3C00.GBP","LU0498741890.SGD","LU1923623000.USD","BK4139","LU0158827781.USD","IDNA","SPLTRmain","LU2362540622.SGD","LU0648000940.SGD","IE00BZ1G4Q59.USD","SCHM","SMYY","LU1551013342.USD","LU0963586101.USD","BK4547","LU0054578231.USD","PLTY","IE00B19Z9P08.USD","BK4527","IE00B19Z9Z06.USD","BK4567","LU0345780281.USD","LU2517655291.USD","NOWL","BK4134","SMCX","LU0234570918.USD","LU0689472784.USD","LU0648001328.SGD","LU1153585028.USD","IE00B19Z3581.USD","LU0314104364.USD","LU1861215975.USD","LU0154245673.USD","SGDM","CLOD","LU0158827948.USD","LU0654597011.USD","LU2125909759.SGD","LU0612318971.USD","IE00B894F039.SGD","IE00BJTD4V19.USD","LU0289739699.SGD","LU1551013425.SGD","LU0823434583.USD","NOW","IE00B19Z8W00.USD","LU0354030511.USD","GUNZ","LU0109391861.USD","LU0011850046.USD","LU0823434740.USD","LU0082616367.USD","BK4607","BK4613","LU0345780521.USD","BK4561","LU1496350171.SGD","SNDK","LU2458330169.SGD","IE0002270589.USD","LU1989764664.SGD","LU1861558580.USD","LU0052756011.USD","LU2106854487.HKD","BK4017","PTIR","LU1280957306.USD","FCUS","CRM","LU0708995401.HKD","LU2462611646.USD","LU2271345857.HKD","PLYY","LU0267386448.USD","SNDU","LU2023250843.SGD","BK4588","LU1267930730.SGD","LU1988902786.USD","LU0289739343.SGD","LU0943347566.SGD","LU0353189763.USD","IE00BQXX3F31.USD","PLTA","PLTI","GDMN","BK4548","BK4535","LU0234572021.USD","LU0889565833.HKD","LU0498741114.HKD","LU0006306889.USD","LU0048573561.USD","PLTD","LU2517655374.HKD","LU1223082519.USD","LU0353189680.USD","SMCY","SNXX","LU0057025933.USD","LU1116320737.USD","SMCL","TRUM","SCHA","PLTU","LU1267930813.SGD","LU0820562030.AUD","LU1430597077.USD","LU0528227936.USD","LU0345781412.USD","IE00BQXX3D17.EUR","PLTL","LU0198837287.USD","CNAV","LU0130517989.USD","LU0354030438.USD","LU0058720904.USD","LU2543165471.USD","NOWX","LU0053671581.USD","LU2756315664.SGD","PTF","LU2089284900.SGD","BK4608","LU0211328371.USD","PLOO","QQQG","LU1316542783.SGD","LU1989772840.SGD","LU1861220033.SGD","LU0130102774.USD","BK4551","LU1823568750.SGD","NEM","LU2236285917.USD","SMCI","LU0511384066.AUD","MRNY","IE00B19Z8X17.USD","LU0251142724.SGD","MRNX","AUAU","LU2381873111.SGD","LU0640476718.USD","IE00BKVL7J92.USD","LU1064131342.USD","LU2357305700.SGD","PLTG","LU1267930227.SGD","IE00B19Z9505.USD","LU0368265764.SGD","BK4125","BK4538","LU2087625088.SGD","LU0689626769.HKD","IE00BMPRXR70.SGD","LU0300736492.USD","LU0630314457.HKD","SMCZ","LU2111349929.HKD","MRNA","LU0075056555.USD","LU2290526834.HKD","LU1804176565.USD","LU1223083913.SGD","BK4023","SHLD","LU0889566641.SGD","LU1923622291.USD","LU0788109121.HKD","LU0310800965.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897568","title":"American Tungsten & Antimony Taps Finland Firm for Scoping Study; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897568","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664897568?lang=en_us&edition=fundamental","pubTime":"2026-09-01 08:28","pubTimestamp":1788222490,"startTime":"0","endTime":"0","summary":"American Tungsten & Antimony  engaged Metso Finland to complete a front-end loading stage one scoping study for an ammonium paratungstate  production circuit at the Del Sol Refinery in Nevada, according to a Tuesday filing with the Australian bourse.The study will assess an APT circuit within the permitted facility as an alternative to a standalone greenfield tungsten processing plant, the filing said.The refinery is the subject of the share sale and purchase agreement disclosed by the company in July.The acquisition has not yet completed, per the filing.American Tungsten & Antimony shares rose 4% in morning trade Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","BK4086","APT.AU","BK4117","BK4568","BK4107","AT4.AU","APT","AFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881857","title":"Did Targeted XFG COVID Shots Just Recenter Pfizer's (PFE) Post‑Pandemic Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881857","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881857?lang=en_us&edition=fundamental","pubTime":"2026-09-01 07:16","pubTimestamp":1788218161,"startTime":"0","endTime":"0","summary":"Pfizer and BioNTech previously received FDA approval for their 2026–2027 COMIRNATY XFG mRNA COVID-19 vaccine, tailored to the XFG variant, for adults 65+ and high-risk individuals aged 5–64, with U.S. distribution beginning shortly after approval.\nThis targeted approval keeps Pfizer’s mRNA platform actively in use for high‑risk populations and aligns the company’s vaccine portfolio with the FDA’s latest variant-composition guidance.\nWe’ll now examine how ongoing XFG-variant vaccine shipments...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/162270-main-header/1756254067137","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/162270-main-header/1756254067137"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/did-targeted-xfg-covid-shots-just-recenter-pfizers-pfe-postp","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/did-targeted-xfg-covid-shots-just-recenter-pfizers-pfe-postp","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0170899867.USD","LU0306807586.USD","OZEM","SG9999002224.SGD","BK4550","LU0058720904.USD","LU0456855351.SGD","BK4592","LU0225284248.USD","LU1023059063.AUD","SG9999011175.SGD","BK4599","SG9999003800.SGD","LU2596442595.SGD","LU0306806265.USD","LU0985481810.HKD","LU1883839398.USD","PFE","SG9999013999.USD","IE000M9KFDE8.USD","LU1066051498.USD","BK4585","BK4533","IE0002270589.USD","IE00B19Z3581.USD","LU1894683264.USD","LU0234572021.USD","LU1894683348.USD","BK4581","SG9999001176.SGD","IE00B3T34201.USD","LU1066053197.SGD","SG9999002232.USD","SGXZ57979304.SGD","BK4568","LU0289739699.SGD","LU0122379950.USD","BK4534","IE00BBT3K403.USD","IE00BLSP4239.USD","LU0225771236.USD","BK4007","LU0321505868.SGD","BK4588","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","SG9999001176.USD","LU1057294990.SGD","LU0868494617.USD","LU0321505439.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664988558","title":"Novavax Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2664988558","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664988558?lang=en_us&edition=fundamental","pubTime":"2026-09-01 05:28","pubTimestamp":1788211680,"startTime":"0","endTime":"0","summary":"DJ Novavax Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Novavax Inc.  advanced 1.19% to $9.37 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index  falling 0.12% to 26,370.89 and Dow Jones Industrial Average  falling 0.70% to 53,185.90.This was the stock's second consecutive day of gains.Novavax Inc. closed 21.72% below its 52-week high of $11.97, which the company achieved on February 26th.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Johnson & Johnson  fell 0.82% to $265.85, Pfizer Inc.  rose 1.79% to $28.46, and Merck & Co. Inc.  fell 0.40% to $147.76.Trading volume  eclipsed its 50-day average volume of 4.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled August 31, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4585","NVAX","BK4588","BK4547","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664398885","title":"Inovio Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2664398885","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664398885?lang=en_us&edition=fundamental","pubTime":"2026-09-01 05:25","pubTimestamp":1788211500,"startTime":"0","endTime":"0","summary":"DJ Inovio Pharmaceuticals Inc. Stock Underperforms Monday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Inovio Pharmaceuticals Inc.  shed 1.55% to $1.27 Monday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index  falling 0.12% to 26,370.89 and Dow Jones Industrial Average  falling 0.70% to 53,185.90.Inovio Pharmaceuticals Inc. closed 57.37% short of its 52-week high of $2.98, which the company reached on September 9th.The stock underperformed when compared to some of its competitors Monday, as Johnson & Johnson  fell 0.82% to $265.85, Statera Biopharma Inc.  rose 100.00% to $0.00, and Pfizer Inc.  rose 1.79% to $28.46.Trading volume  eclipsed its 50-day average volume of 3.8 M.Data source: Dow Jones Market Data, FactSet. Data compiled August 31, 2026.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INO","BK4583","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664839598","title":"Pfizer Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2664839598","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664839598?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:36","pubTimestamp":1788208560,"startTime":"0","endTime":"0","summary":"DJ Pfizer Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Pfizer Inc.  advanced 1.79% to $28.46 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 0.33% to 7,686.14 and Dow Jones Industrial Average  falling 0.70% to 53,185.90.The stock's rise snapped a three-day losing streak.Pfizer Inc. closed 0.99% below its 52-week high of $28.75, which the company reached on April 2nd.The stock outperformed some of its competitors Monday, as Johnson & Johnson  fell 0.82% to $265.85, Eli Lilly & Co.  fell 1.52% to $1,156.73, and Abbott Laboratories  fell 1.88% to $110.36.Trading volume  eclipsed its 50-day average volume of 44.0 M.Data source: Dow Jones Market Data, FactSet. Data compiled August 31, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999013999.USD","BK4592","LU1057294990.SGD","SG9999001176.USD","LU0868494617.USD","IE00BLSP4239.USD","SG9999011175.SGD","BK4585","IE00B19Z3B42.SGD","LU0225284248.USD","SGXZ57979304.SGD","LU0058720904.USD","BK4568","LU0456855351.SGD","IE0002270589.USD","BK4534","BK4533","LU1066051498.USD","BK4581","IE000M9KFDE8.USD","LU0321505868.SGD","LU2596442595.SGD","LU0170899867.USD","SG9999002224.SGD","BK4599","LU1883839398.USD","SG9999003800.SGD","OZEM","IE00B19Z3581.USD","LU0289739699.SGD","LU0985481810.HKD","LU1894683264.USD","SG9999002232.USD","LU1023059063.AUD","LU0234572021.USD","IE00BLSP4452.SGD","LU1894683348.USD","LU0306806265.USD","BK4550","IE00B3T34201.USD","LU0321505439.SGD","PFE","LU1066053197.SGD","LU0225771236.USD","LU0306807586.USD","BK4588","LU0122379950.USD","SG9999001176.SGD","BK4007","IE00BBT3K403.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883666","title":"Abbott Laboratories Stock Underperforms Monday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883666","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883666?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:35","pubTimestamp":1788208500,"startTime":"0","endTime":"0","summary":"DJ Abbott Laboratories Stock Underperforms Monday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Abbott Laboratories  slid 1.88% to $110.36 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index  falling 0.33% to 7,686.14 and Dow Jones Industrial Average  falling 0.70% to 53,185.90.Abbott Laboratories closed 19.73% below its 52-week high of $137.49, which the company reached on September 22nd.The stock underperformed when compared to some of its competitors Monday, as Johnson & Johnson  fell 0.82% to $265.85, Pfizer Inc.  rose 1.79% to $28.46, and Merck & Co. Inc.  fell 0.40% to $147.76.Trading volume  remained 746,173 below its 50-day average volume of 11.3 M.Data source: Dow Jones Market Data, FactSet. Data compiled August 31, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","IE0002141913.USD","LU1691799644.USD","PJP","IE00BJT1NW94.SGD","LU1057294990.SGD","LU1061106388.HKD","LU1989763427.SGD","LU0208291251.USD","LU2211815571.USD","LU2237957811.SGD","LU1989763690.USD","LU0320765489.SGD","SG9999004303.SGD","LU2089984988.USD","BK4533","LU1023059063.AUD","LU2112291526.USD","SG9999002224.SGD","LU2324357040.USD","LU0882574055.USD","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU0868494617.USD","LU1721429741.USD","LU2237957902.USD","BK4568","IE00BJJMRZ35.SGD","BK4082","IE00B2B36J28.USD","BK4504","LU0122379950.USD","LU1670627923.USD","LU1670628061.USD","LU1721429402.USD","LU0211331839.USD","LU0432979614.USD","BK4588","BK4592","BK4585","SG9999002232.USD","IE00B4R5TH58.HKD","IE0009355771.USD","SGXZ41872573.SGD","LU0234572021.USD","BK4566","BK4581","ABT","LU0114720955.EUR","TMED","LU0266013472.USD","SGXZ23171101.USD","LU0170899867.USD","LU0289739699.SGD","IHI","LU1914381329.SGD","LU0070302665.USD","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000652","title":"Cboe data suggests bullish flow in Moderna with shares up 0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664000652?lang=en_us&edition=fundamental","pubTime":"2026-09-01 02:20","pubTimestamp":1788200410,"startTime":"0","endTime":"0","summary":"Cboe data suggests bullish flow in Moderna (MRNA), with shares up 98c, or 0.71%, near $138.97. Options volume relatively light with 62k contracts t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cboe-data-suggests-bullish-flow-in-moderna-with-shares-up-0-71-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cboe-data-suggests-bullish-flow-in-moderna-with-shares-up-0-71-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4532","BK4139","GNOM","BK4548","MRNY","BK4501","MRNA","BK4588","IDNA","BK4551","MRNX","WDNA","BK4568","BK4533","LGHT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664200767","title":"Moderna Stock (MRNA) Was the Best Performer in August","url":"https://stock-news.laohu8.com/highlight/detail?id=2664200767","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664200767?lang=en_us&edition=fundamental","pubTime":"2026-09-01 01:18","pubTimestamp":1788196728,"startTime":"0","endTime":"0","summary":"Moderna’s ($MRNA) stock rose 152% in August, making it the best-performing security during the month.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/moderna-stock-mrna-was-the-best-performer-in-august?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/moderna-stock-mrna-was-the-best-performer-in-august?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4501","MRNY","BK4551","LGHT","MRNX","BK4532","BK4533","BK4139","BK4568","BK4548","GNOM","IDNA","BK4585","MRNA","BK4534","BK4588","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664002661","title":"AstraZeneca PLC Stock Rises Monday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2664002661","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664002661?lang=en_us&edition=fundamental","pubTime":"2026-09-01 00:00","pubTimestamp":1788192000,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of AstraZeneca PLC advanced 0.3% to SEK1,563.50 Monday on what proved to be an overall negative trading session for the stock market, with the OMX Nordic 40 Index falling 0.9% to 2,707.24.The stock's rise  snapped a three-day losing streak.The company closed SEK362.00 below its 52-week high of SEK1,925.50, which the company reached on April 10, 2026.Trading volume was 352,573, compared to the 50-day average trading volume of 546,664.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","BK4585","LU0432979614.USD","LU0708994859.HKD","LU0889565916.HKD","LU2468319806.SGD","BK4568","BK4588","LU2089984988.USD","LU0058720904.USD","AZN","LU2237443382.USD","LU0310800379.SGD","LU2237443895.HKD","LU1267930573.SGD","LU0109394709.USD","LU2417539215.USD","LU1829250122.USD","LU2456880835.USD","IE00B3T34201.USD","LU0320765992.SGD","LU2237443549.SGD","LU0128525929.USD","LU2237443978.SGD","LU2237443622.USD","BK4007","LU0289739699.SGD","LU2236285917.USD","LU2462157665.USD","LU2237443465.HKD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663515009","title":"Aethlon Medical Completes Warrant Exercises, Clarifying Capitalization","url":"https://stock-news.laohu8.com/highlight/detail?id=2663515009","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663515009?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:51","pubTimestamp":1788184315,"startTime":"0","endTime":"0","summary":"An announcement from Aethlon Medical ( ($AEMD) ) is now available. Aethlon Medical, Inc. reported that, following recent exercises of certain pre-f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-completes-warrant-exercises-clarifying-capitalization?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-completes-warrant-exercises-clarifying-capitalization?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4583","BK4082","AEMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663966006","title":"China's Ascletis Pharma H1 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2663966006","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663966006?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:31","pubTimestamp":1788183111,"startTime":"0","endTime":"0","summary":"China's Ascletis Pharma H1 net loss widens on higher R&D costsOverviewChina biopharma developer's interim net loss widened 263% yr/yr to RMB319.7 mlnTotal income for the period fell 49% yr/yrR&D expen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0IE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","BK1161","BK4585","BK4568","BK1574","01672","BK4551","BK1515","01228","BK4548","BNTX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663057430","title":"Aethlon Medical Says All Pre-Funded Warrants are Exercised","url":"https://stock-news.laohu8.com/highlight/detail?id=2663057430","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663057430?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:15","pubTimestamp":1788182150,"startTime":"0","endTime":"0","summary":"Aethlon Medical says all pre-funded warrants are exercisedAethlon Medical reported all previously outstanding pre-funded warrants were exercised following recent warrant exercises.Common shares outsta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLc5SWhH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4583","BK4082","AEMD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}